Last reviewed · How we verify

NCT03931226: PEDIATHERM

Impact of Spa Treatments on the Consumption of Care in Children

Completed Last updated 13 November 2023
What this trial tests

trial testing Drug consumption in Respiratory Disease in 8,372 participants. Completed in 31 December 2022.

Timeline
1 June 2018
Primary endpoint
31 December 2022
31 December 2022

Quick facts

Lead sponsorUniversity Hospital, Toulouse
StatusCompleted
Study typeOBSERVATIONAL
Enrollment8,372
Start date1 June 2018
Primary completion31 December 2022
Estimated completion31 December 2022
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Toulouse

Who can join

Adults 1 to 15, any sex, with Respiratory Disease or Otorhinolaryngologic Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Children represent 1.2% of the spa population in France. Spa treatments, including climatic stays, are mainly prescribed for children in the context of respiratory, otorhinolaryngology and dermatological conditions. The benefits after spa treatments are the improvement of the symptoms of the pathology, the quality of life and in particular the reduction of drug exposures. Few authors have recently investigated the impact of spa treatments on the health of children and society, while care has changed significantly in recent years. Moreover, no real-life study of a large sample of children seems to have been conducted in this area. The present study plan to conduct a pharmacoepidemiology study on medico-administrative databases of the "observational study" type, in real life.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Respiratory Disease

Currently open trials in the same condition.

Other University Hospital, Toulouse trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03931226.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing